Copyright
©The Author(s) 2024.
World J Gastroenterol. May 21, 2024; 30(19): 2512-2522
Published online May 21, 2024. doi: 10.3748/wjg.v30.i19.2512
Published online May 21, 2024. doi: 10.3748/wjg.v30.i19.2512
Figure 2 Median overall survival shown in clinical trials by drugs approved as first-line systemic therapy, compared with sorafenib.
IMbrave150 analyzed atezolizumab + bevalizumab. HIMALAYA investigated durvalumab + tremelimumab.
- Citation: Urquijo-Ponce JJ, Alventosa-Mateu C, Latorre-Sánchez M, Castelló-Miralles I, Diago M. Present and future of new systemic therapies for early and intermediate stages of hepatocellular carcinoma. World J Gastroenterol 2024; 30(19): 2512-2522
- URL: https://www.wjgnet.com/1007-9327/full/v30/i19/2512.htm
- DOI: https://dx.doi.org/10.3748/wjg.v30.i19.2512